Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–11. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6–23. doi:10.1111/imr.12766.
   PubMed Web of Science ®Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–1778. doi:10.1056/NEJMra1514296.
   PubMed Web of Science ®Google Scholar
• Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Domling A, Dubin G, Holak TA. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341–2348. doi:10.1016/j.str.2015.09.010.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang S, Zhang Y, Zhu L, Wu X. The application and mechanism of PD pathway blockade for cancer therapy. Postgrad Med J. 2018;94(1107):53–60. doi:10.1136/postgradmedj-2017-135187.
   PubMed Web of Science ®Google Scholar
• Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. doi:10.1186/s13045-019-0779-5.
   PubMed Web of Science ®Google Scholar
• Zhan MM, Hu XQ, Liu XX, Ruan BF, Xu J, Liao C. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug Discov Today. 2016;21(6):1027–1036. doi:10.1016/j.drudis.2016.04.011.
   PubMed Web of Science ®Google Scholar
• Yang J, Hu L. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: from antibodies to small molecules. Med Res Rev. 2019;39:265–301.
   PubMed Web of Science ®Google Scholar
• Wu L, Xiao K, Yao. W. Heterocyclic compounds as immunomodulators. In. Edited by Incyte Corporation W, DE (US). US; 2020.
   Google Scholar
• Aktoudianakis E, Cho A, Graupe M, Lad LT, Tello PAM, Medley JW, Metobo SE, Naduthambi D, Phillips BW, Simonovich. SP, et al. PD-1/PD-L1 inhibitors. In. Edited by Gilead Sciences I, Foster City, CA (US). US; 2020.
   Google Scholar
• Sasikumar PGN, Ramachandra M, Naremaddepalli SSS. Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators. In: Edited by Aurigene Discovery Technologies Limited BI. Bangalore (IN): US: Aurigene Discovery Technologies Limited; 2018.
   Google Scholar
• Minghua W. Symmetric or semi-symmetric compounds useful as immunomodulators. In. Edited by Arising International LU; 2019.
   Google Scholar
• Qi C, Konkol LC, Wu L, Lajkiewicz N, He C, Xiao K, Zhu W, Li Z, Mei S, Yao W. Bicyclic heteroaromatic compounds as immunomodulators. In. Edited by Incyte Corporation W, DE (US); 2018.
   Google Scholar
• Wu L, Yu Z, Zhang F, Yao W. Pyridine derivatives as immunomodulators. In. Edited by Incyte Corporation W, DE (US); 2018.
   Google Scholar
• Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2018;1–13.
   Web of Science ®Google Scholar
• Musielak B, Kocik J, Skalniak L, Magiera-Mularz K, Sala D, Czub M, Stec M, Siedlar M, Holak TA, Plewka J. CA-170 - a potent small-molecule PD-L1 inhibitor or not? Molecules. 2019;24(15):2804. doi:10.3390/molecules24152804.
   PubMed Web of Science ®Google Scholar
• Ganesan A, Ahmed M, Okoye I, Arutyunova E, Babu D, Turnbull WL, Kundu JK, Shields J, Agopsowicz KC, Xu L, et al. Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Sci Rep. 2019;9(1):12392. doi:10.1038/s41598-019-48826-6.
   PubMed Web of Science ®Google Scholar
• Blevins DJ, Hanley R, Bolduc T, Powell DA, Gignac M, Walker K, Carr MD, Hof F, JE W. In vitro assessment of putative PD-1/PD-L1 Inhibitors: suggestions of an alternative mode of action. ACS Med Chem Lett. 2019;10(8):1187–1192. doi:10.1021/acsmedchemlett.9b00221.
   PubMed Web of Science ®Google Scholar
• S Dm CL, Martin Scotte W, Xiaofan Z, Piyasena H, Connolly Timothy P, Ningning X, Kap-sun Y, Juliang Z, Langley DR, Tenney DJ, et al. Compounds useful as immunomodulators. In. Edited by Squibb B-M. US; 2015.
   Google Scholar
• Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, Dubin G, Holak TA. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016;7(21):30323–30335. doi:10.18632/oncotarget.8730.
   PubMedGoogle Scholar
• Schwarz F, Aebi M. Mechanisms and principles of N-linked protein glycosylation. Curr Opin Struct Biol. 2011;21(5):576–582. doi:10.1016/j.sbi.2011.08.005.
   PubMed Web of Science ®Google Scholar
• Li C-W, Lim S-O, Xia W, Lee -H-H, Chan L-C, Kuo C-W, Khoo K-H, Chang -S-S, Cha J-H, Kim. T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632. doi:10.1038/ncomms12632.
   PubMed Web of Science ®Google Scholar
• Lopez-Sambrooks C, Shrimal S, Khodier C, Flaherty DP, Rinis N, Charest JC, Gao N, Zhao P, Wells L, Lewis TA, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016;12(12):1023–1030. doi:10.1038/nchembio.2194.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33(2):187–201e110. doi:10.1016/j.ccell.2018.01.009.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S, et al. Aberrant PD-L1 expression through 3ʹ-UTR disruption in multiple cancers. Nature. 2016;534(7607):402–406.
   PubMed Web of Science ®Google Scholar
• Maher CM, Thomas JD, Haas DA, Longen CG, Oyer HM, Tong JY, Kim FJ. Small-molecule Sigma1 modulator induces autophagic degradation of PD-L1. Mole Cancer Res. 2018;16(2):243–255. doi:10.1158/1541-7786.MCR-17-0166.
   PubMed Web of Science ®Google Scholar
• Contessa JN, Bhojani MS, Freeze HH, Rehemtulla A, Lawrence TS. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res. 2008;68(10):3803–3809. doi:10.1158/0008-5472.CAN-07-6389.
   PubMed Web of Science ®Google Scholar
• Roth Z, Yehezkel G, Khalaila I. Identification and quantification of protein glycosylation. Int J Carbohydr Chem. 2012;2012:1–10. doi:10.1155/2012/640923.
   Google Scholar
• Nakamura N. Characterization of a cis-Golgi matrix protein, GM130. J Cell Biol. 1995;131(6):1715–1726. doi:10.1083/jcb.131.6.1715.
   PubMed Web of Science ®Google Scholar
• Chung CY, Majewska NI, Wang Q, Paul JT, Betenbaugh MJ. SnapShot: N-glycosylation processing pathways across kingdoms. Cell. 2017;171(1):258–258e251. doi:10.1016/j.cell.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Benyair R, Ogen-Shtern N, Lederkremer GZ. Glycan regulation of ER-associated degradation through compartmentalization. Semin Cell Dev Biol. 2015;41:99–109. doi:10.1016/j.semcdb.2014.11.006.
   PubMed Web of Science ®Google Scholar
• Wang L, Yu C, Yang Y, Gao K, Wang J. Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies. J Pharm Biomed Anal. 2017;145:447–453. doi:10.1016/j.jpba.2017.05.011.
   PubMed Web of Science ®Google Scholar
• Macia F, Ga-Cz F, Im S-H, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell. 2002;109:719–731. doi:10.1016/S0092-8674(02)00767-5.
   PubMed Web of Science ®Google Scholar
• KMZ LS, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, et al. Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 2017;8(42):72167–72181. doi:10.18632/oncotarget.20050.
   PubMedGoogle Scholar
• Tocheva AS, Lerrer S, Mor A. In vitro assays to study PD-1 biology in human T cells. Curr Protoc Immunol. 2020;130:e103.
   PubMedGoogle Scholar
• Gary R, Voelkl S, Palmisano R, Ullrich E, Bosch JJ, Mackensen A. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. J Immunol. 2012;188(2):744–752. doi:10.4049/jimmunol.1101412.
   PubMed Web of Science ®Google Scholar
• Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, Khoo KH, Chang SS, Cha JH, Kim T, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7(12632).
   Google Scholar
• Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71(4):606–620e607. doi:10.1016/j.molcel.2018.07.030.
   PubMed Web of Science ®Google Scholar
• Sara Verdura EC, Cortada E, Brunet J, Lopez-Bonet E, Martin-Castillo B, Bosch-Barrera J, Encinar JA, Menendez JA. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging. 2020;12(1):8–34. doi:10.18632/aging.102646.
   PubMedGoogle Scholar
• Kim B, Sun R, Oh W, Kim AMJ, Schwarz JR, Lim SO. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation. Mol Carcinog. 2020;59(7):691–700. doi:10.1002/mc.23170.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Fang Wei SZ, Zhengyu M, Kong H, Medvec A, Rafi Ahmed GJ, Freeman MK, Riley JL. Strength of PD-1 signaling differentially affects T-cell effector functions. PNAS. 2013;110(27):E2480–E2489. doi:10.1073/pnas.1305394110.
   PubMed Web of Science ®Google Scholar
• Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12(6):492–499. doi:10.1038/ni.2035.
   PubMed Web of Science ®Google Scholar
• Chen F, Song Q, Yu Q. Axl inhibitor R428 induces apoptosis of cancer cells by blocking lysosomal acidification and recycling independent of Axl inhibition. Am J Cancer Res. 2018;8:1466–1482.
   PubMed Web of Science ®Google Scholar
• Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R, Dolstra H. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood. 2010;116(22):4501–4511. doi:10.1182/blood-2010-04-278739.
   PubMed Web of Science ®Google Scholar
• Rahman M, Nara H, Onoda T, Araki A, Li J, Hoshino T, Asao H. Cloning and characterization of an isoform of interleukin-21. FEBS Lett. 2007;581(21):4001–4009. doi:10.1016/j.febslet.2007.07.034.
   PubMed Web of Science ®Google Scholar
• Marischen L, Englert A, Schmitt AL, Einsele H, Loeffler J. Human NK cells adapt their immune response towards increasing multiplicities of infection of Aspergillus fumigatus. BMC Immunol. 2018;19(1):39. doi:10.1186/s12865-018-0276-6.
   PubMed Web of Science ®Google Scholar
• Liu JY, Li F, Wang LP, Chen XF, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne SH, et al. CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. Br J Cancer. 2015;113(5):747–755. doi:10.1038/bjc.2015.290.
   PubMed Web of Science ®Google Scholar
• Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40(1):185–194. doi:10.1002/hep.20283.
   PubMed Web of Science ®Google Scholar
• Bedi A, Chang X, Noonan K, Pham V, Bedi R, Fertig EJ, Considine M, Califano JA, Borrello I, Chung CH, et al. Inhibition of TGF-beta enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy. Mol Cancer Ther. 2012;11(11):2429–2439. doi:10.1158/1535-7163.MCT-12-0101-T.
   PubMed Web of Science ®Google Scholar
• Guo H, Kuang S, Song QL, Liu M, Sun XX, Yu Q. Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments. Acta Pharmacol Sin. 2018;39(3):425–437. doi:10.1038/aps.2017.99.
   PubMed Web of Science ®Google Scholar